Department of Cell Biology, NYU School of Medicine, New York, NY, USA.
Department of Microbiology, NYU School of Medicine, New York, NY, USA.
EMBO J. 2023 Aug 1;42(15):e114912. doi: 10.15252/embj.2023114912. Epub 2023 Jul 12.
The diarylquinoline bedaquiline (BDQ) is an FDA-approved drug for the treatment of multidrug-resistant tuberculosis that targets the mycobacterial adenosine triphosphate (ATP) synthase, a key enzyme in cellular respiration. In a recent study, Courbon et al (2023) examine the interaction between Mycobacterium smegmatis ATP synthase with the second generation diarylquinoline TBAJ-876 and the squaramide inhibitor SQ31f, showing that both drugs prevent the rotatory motions needed for enzymatic function.
二芳基喹啉类药物贝达喹啉（BDQ）是一种经美国食品药品监督管理局批准用于治疗耐多药结核病的药物，其作用靶点是分枝杆菌三磷酸腺苷（ATP）合酶，这是细胞呼吸的关键酶。在最近的一项研究中，Courbon 等人（2023 年）研究了分枝杆菌 ATP 合酶与第二代二芳基喹啉 TBAJ-876 和 squaramide 抑制剂 SQ31f 的相互作用，结果表明这两种药物都能阻止酶功能所需的旋转运动。
